Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
03/04/2004 | US20040043922 Treatment of case-ready food products with immobilized lactoferrin (Im-LF) and the products so produced |
03/04/2004 | US20040043463 Comprises inhibitory fusion protein topical for treating aberration affecting hair pigmentation, skin pigmentation and/or skin conditioning |
03/04/2004 | US20040043417 Generation and screening of a dynamic combinatorial library |
03/04/2004 | US20040043076 Containing protein active material; solvent-free |
03/04/2004 | US20040043074 Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
03/04/2004 | US20040043072 Alleviation of upper gastrointestinal irritation |
03/04/2004 | US20040043067 Fluorosiloxane matrix controlled diffusion drug delivery systems |
03/04/2004 | US20040043043 Gelling, thickening solutions of water soluble vitamins with triglycerides and emulsifiers |
03/04/2004 | US20040043038 Vaccines |
03/04/2004 | US20040043030 Polymeric delivery systems |
03/04/2004 | US20040043029 Novel antibodies reactive with human carcinomas |
03/04/2004 | US20040043007 Transfection system |
03/04/2004 | US20040043002 Polyol-IFN-beta conjugate and composition containing same |
03/04/2004 | US20040043001 Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
03/04/2004 | US20040042990 Composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer, and use thereof |
03/04/2004 | US20040042973 Anhydrous mometasome furoate mixture with surfactant and propellant; pressurized vessel; controlling particle size distribution |
03/04/2004 | US20040042961 Using mutant green fluorescent protein |
03/04/2004 | US20040040227 Material for improving living environment, and building material, laying material and spraying agent using the same |
03/04/2004 | DE10261126A1 Lagerungsstabile, flüssige Fibrinogen-Formulierung Storage stable liquid fibrinogen formulation |
03/04/2004 | DE10239999A1 Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen Granules or powders for the preparation of coatings and binders for pharmaceutical forms |
03/04/2004 | CA2733212A1 Arginine silicate inositol complex and use thereof |
03/04/2004 | CA2496952A1 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
03/04/2004 | CA2496422A1 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
03/04/2004 | CA2496376A1 Methods of drug delivery using sulphated chitinous polymers |
03/04/2004 | CA2495923A1 Methods for treating fungal infections |
03/04/2004 | CA2495913A1 Non-vesicular cationic lipid formulations |
03/04/2004 | CA2495689A1 Pharmaceutical compositions |
03/04/2004 | CA2494974A1 Il-7 drug substance, composition, preparation and uses |
03/04/2004 | CA2491758A1 Blood clot-targeted nanoparticles |
03/03/2004 | EP1394180A1 Synthetic mimetic molecules of physiological binding molecules |
03/03/2004 | EP1393750A2 Conjugates for treating an immune disease |
03/03/2004 | EP1393749A1 A pharmaceutical preparation in colloidal form useful in the treatment of skin diseases, comprising hyluronic acid |
03/03/2004 | EP1393741A1 Storage-stable, liquid fibrinogen-formulation |
03/03/2004 | EP1393732A1 Minoxidil-containing liquid composition |
03/03/2004 | EP1393723A2 Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
03/03/2004 | EP1393721A1 Dosage form of powder agglomerates |
03/03/2004 | EP1393719A1 Camptothecin-carboxylate formulations |
03/03/2004 | EP1393713A1 Liquid concentrate for the preservation of cosmetic and pharmaceutical products |
03/03/2004 | EP1392846A2 METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING |
03/03/2004 | EP1392756A2 Lipid-polymer-conjugates |
03/03/2004 | EP1392755A1 Lipid-polymer-conjugates compositions |
03/03/2004 | EP1392751A1 Biodegradable copolymers linked to segment with a plurality of functional groups |
03/03/2004 | EP1392714A1 Steroids as agonists for fxr |
03/03/2004 | EP1392666A1 Biologically active methylene blue derivatives |
03/03/2004 | EP1392485A1 Method for injection moulding moulded bodies consisting of (meth)acrylate copolymers |
03/03/2004 | EP1392389A2 Microprojection array having a beneficial agent containing coating |
03/03/2004 | EP1392375A2 Composition and use of substances for stabilising amino acids containing sulphur |
03/03/2004 | EP1392366A1 Nuclear receptor-mediated introduction of a pna into cell nuclei |
03/03/2004 | EP1392365A2 Compositions and therapeutical use of polynucleotides encoding tcrs |
03/03/2004 | EP1392364A2 Liquid polymer composition for prevention and treatment of the oral cavity diseases |
03/03/2004 | EP1392360A2 Modified antibodies to prostate-specific membrane antigen and uses thereof |
03/03/2004 | EP1392337A1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
03/03/2004 | EP1392327A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |
03/03/2004 | EP1392325A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
03/03/2004 | EP1392321A1 Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
03/03/2004 | EP1392297A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
03/03/2004 | EP1392293A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
03/03/2004 | EP1392279A1 Trimethyl lock based tetrapartate prodrugs |
03/03/2004 | EP1392272A1 Permeation enhancers |
03/03/2004 | EP1392264A1 Delivery of antiemetics through an inhalation route |
03/03/2004 | EP1392262A1 Delivery of drug esters through an inhalation route |
03/03/2004 | EP1392261A2 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
03/03/2004 | EP1392259A2 Delivery of erectile dysfunction drugs through an inhalation route |
03/03/2004 | EP1392258A2 Delivery of alprazolam, estazolam, midazolam or triazolam throughan inhalation route |
03/03/2004 | EP1392257A1 Delivery of antihistamines through an inhalation route |
03/03/2004 | EP1392256A1 Improved transdermal therapeutic system for the treatment of parkinson's disese |
03/03/2004 | EP1392255A1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
03/03/2004 | EP1392254A1 Micellar drug delivery systems for hydrophobic drugs |
03/03/2004 | EP1392253A2 Gelatin substitute |
03/03/2004 | EP1392250A2 Controlled release dosage forms using acrylic polymer, and process for making the same |
03/03/2004 | EP1392249A1 Nsaid formulation comprising a granular composition and an extra-granular composition |
03/03/2004 | EP1392246A1 Compaction process for manufacture of sodium phenytoin dosage form |
03/03/2004 | EP1392244A2 Pharmaceutical compositions |
03/03/2004 | EP1392241A2 System for osmotic delivery of pharmaceutically active agents |
03/03/2004 | EP1392204A2 Bifunctional energy-reversible acyl-compositions |
03/03/2004 | EP1392116A1 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds |
03/03/2004 | EP1392115A1 Controlled release particles |
03/03/2004 | EP1259128A4 Water containing soluble fiber |
03/03/2004 | EP1169064B1 Method of detecting endometriosis |
03/03/2004 | EP1162953B1 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances |
03/03/2004 | EP1140020B1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
03/03/2004 | EP1140012B1 Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
03/03/2004 | EP1113787B1 Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
03/03/2004 | EP1037615B1 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
03/03/2004 | EP1019025B1 Peptide/lipid complex formation by co-lyophilization |
03/03/2004 | EP0938341B1 Compositions and methods for altering the biodistribution of biological agents |
03/03/2004 | EP0893992B1 Fast disintegrating oral dosage form |
03/03/2004 | EP0874558B8 Liquid oral compositions comprising a calcium compound and an acidulant |
03/03/2004 | EP0859628B9 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
03/03/2004 | EP0831850B1 Use of locally applied dna fragments |
03/03/2004 | EP0749304B2 Slow-release tablet containing diclofenac-na |
03/03/2004 | EP0636028B1 Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide |
03/03/2004 | CN1479632A Complexes for transferring necleic acids into cells |
03/03/2004 | CN1479631A Reversible gelling system for ocular drug delivery |
03/03/2004 | CN1479625A Herbal pharmaceutical compositions for treating immun logical disorders |
03/03/2004 | CN1479623A Antimonocytic activity of extracts of piper betel leaves |
03/03/2004 | CN1479620A Oral extended release formulation of gepirone |
03/03/2004 | CN1479617A N-methyl-D-aspartate receptor agonist pharmaceutical compositions |
03/03/2004 | CN1479613A Rapidly disintegrating tablet comprising acid-sensitive active ingredient |
03/03/2004 | CN1479612A Pharmaceutical compositions for oral delivery of pharmacologically active agents |